Reviews/Chronic Spontaneous Urticaria Treatment/Basophil activation test identifies autoimmune chronic spontaneous urticaria
Biomarkers · CSU-BM-02 · v2
Chronic spontaneous urticaria can be driven by antibodies in a patient's blood that switch on the immune cells responsible for hives. The basophil activation test takes a patient's serum, adds it to basophils (usually from a healthy donor), and checks whether activation markers switch on, which flags the antibody-driven form of the disease. Several independent groups found the test turns markers on with sera from patients who are also positive on the older skin test, and the largest studies now use it as one of the defining features of autoimmune CSU [11][25][26][13][14][19]. The catch is that the test reads basophils, not the mast cells named in the claim, and it is positive in only a minority of patients, so a negative result does not rule the condition out [13]. It is also checked mainly against an older skin test that is itself imperfect [24][25][26]. The panel judged the test a real and reproducible marker of the autoimmune subset while noting these limits keep the claim's exact wording from being fully demonstrated.
Independent primary cohorts show patient sera from CSU upregulate basophil activation markers CD203c and CD63, and that this tracks the autoimmune subset: incubating donor basophils with sera from autologous-serum-skin-test-positive patients significantly raised CD203c, an effect abolished by IgG depletion [11], and serum-induced CD63 gave 95.5% sensitivity and 90.5% specificity against the skin test with sera from systemic-autoimmune controls staying negative [25][26]. Individual IL-3 priming of donor basophils made the assay a reproducible alternative to the skin test [8]. In the PURIST study of 182 patients, 46 (25%) were basophil-test positive and a positive test was 69% predictive of autoimmune CSU [13], and in a 1120-patient analysis the test was described as the best single marker, with relative risk 3.636 (95% CI 2.382-5.551) of positivity in the high-anti-TPO low-IgE group [14]. A positive basophil test is embedded in the autoimmune CSU definition in a 111-patient endotype study [19]. The contested point: The evidence measures basophil activation, often in donor basophils incubated with patient serum [11], whereas the claim asserts mast cell activation, which no corpus paper demonstrates directly. The signal also identifies only a minority (46/182 positive, 8% triple-positive in PURIST [13]) and its diagnostic accuracy is benchmarked against the autologous serum skin test, itself positive in 37% of non-CU patients [24].
All 27 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Spontaneous Urticaria Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Surrogate/indirectness: no included paper measures mast cell activation in CSU; every assay measures basophil activation, frequently using donor basophils incubated with patient serum ([11] 'Incubation of donor basophils with sera'). The claim's 'mast cell activation' is inferred, not demonstrated.
Modest sensitivity: BAT identifies only a minority. PURIST [13] reported 46/182 (25%) BASO+ and only 8% fulfilling triple-positive aiCSU; BAT is one of three criteria rather than a stand-alone identifier, so a negative BAT does not exclude autoimmune CSU.
Where it remains uncertain. Every included study measures basophil activation, frequently in donor basophils plus patient serum [11], not the mast cell activation named in the claim, and the test is positive in only 25% of patients with validation leaning on the imperfect skin test [13][24].
Aleatory
Assay output depends on individual donor basophil reactivity; non-responder basophils required individual IL-3 priming for consistent results [8].
Epistemic
Diagnostic performance is measured against the autologous serum skin test [25][26], which is positive in 37% of non-CU patients [24], so true accuracy against mast-cell-driven disease is unknown.
Inferential
The claim's 'mast cell activation' is inferred from a basophil assay; no corpus paper measures mast cell activation in CSU [11].
The load-bearing papers from a corpus of 27, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Supports serum-BAT as a reliable in vitro detector of autoreactive serum components in chronic urticaria.
“The basophil activation test with individualized IL-3 priming for each basophil donor is a reproducible and reliable alternative to the ASST.”
Panel auditInternal validity: medium · scope of inference: Detection of autoreactive serum components in chronic spontaneous urticaria via donor-basophil BAT.Key limitations: degranulating factor identity unresolved · measures basophils not mast cells · no clinical outcome anchor
Primary evidence that CU sera with autoreactivity activate basophils via an IgG-dependent mechanism.
“Incubation of donor basophils with sera from patients with chronic idiopathic urticaria and positive autologous serum skin test demonstrated significant upregulation of CD203c.”
Panel auditInternal validity: medium · scope of inference: CD203c upregulation by CIU sera as a marker of autoantibody activity.Key limitations: ex vivo surrogate not clinical outcome · measures basophils not mast cells · no reported sample size
Quantifies BAT's predictive value for the autoimmune CSU endotype in a 182-patient multinational cohort.
“Of biomarkers, positive BAT and BHRA tests were 69% and 88% predictive of aiCSU, respectively.”
Panel auditInternal validity: high · scope of inference: BAT positivity as a predictor of the autoimmune (type IIb) CSU endotype.Key limitations: BAT is part of the defining criterion (partial circularity) · measures basophils not mast cells · no outcome gold standard beyond composite criteria
Shows BAT-based basophil reactivity resolves immunologic subtypes within chronic urticaria.
“Stimulating CU patients' basophils via FcεRI, we identified three distinct immunologic phenotypes.”
Panel auditInternal validity: medium · scope of inference: Basophil-reactivity-based immunologic subtypes in chronic urticaria.Key limitations: exploratory subtyping · measures basophils not mast cells · no clinical diagnostic-accuracy endpoint
4 of 27 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus supports BAT identifying the autoimmune endotype of CSU robustly and reproducibly, but surrogate indirectness, modest sensitivity, and reliance on an imperfect reference standard cap confidence in the Likely band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Direct mast cell correlate. The claim names mast cell activation but the corpus only measures basophil activation [11], leaving the central inference untested. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A paired study running a mast cell activation test and the basophil activation test on the same CSU sera, correlating both to clinical disease.
Open question: Does a positive basophil activation test correspond to mast cell activation in CSU patients, not only basophil activation? Why it is still open: Every included study measures basophil activation, often using donor basophils incubated with patient serum [11]; none measures mast cell activation.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19